Hypothesis: Intralesional cidofovir should be routinely considered in the treatment of recurrent respiratory papillomatosis (RRP).
Although surgical management remains the mainstay of therapy for RRP, ultimately as many as 20% of patients with the disease will require some form of adjuvant therapy.1The most widely adopted current criteria for initiating adjuvant therapy are a surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and/or rapid regrowth of papilloma disease with airway compromise.2At the present time, there are no medications approved by the US Food and Drug Administration (FDA) with an indication for treatment of RRP.
Derkay C. Use of Cidofovir for Treatment of Recurrent Respiratory Papillomatosis. Arch Otolaryngol Head Neck Surg. 2009;135(2):198-201. doi:10.1001/archoto.2008.539